Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS
NCT02989025Phase 2Recruiting
- Sponsor
- University of Mississippi Medical Center
- Start
- May 2017
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxyprogesterone caproate in preeclampsia (2 arms), sponsored by University of Mississippi Medical Center. Primary endpoint: Improvement of maternal and perinatal outcomes. Started May 2017; status: recruiting.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT02989025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989025.